Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years
Abstract Introduction Psoriasis, a chronic inflammatory skin disease, affects approximately one million Canadians, with plaque psoriasis (PsO) being the most common subtype. While brodalumab has shown efficacy and safety in phase III clinical trials, Canadian real-world evidence remains limited. Thi...
Saved in:
| Main Authors: | Veronique Gaudet, Irina Turchin, Charles W. Lynde, Virginie Kelly, Dusan Sajic, Shazia Hassan, Belinda Yap, Maxime Barakat, Vimal H. Prajapati |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-03-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01369-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning
by: Babaei N, et al.
Published: (2025-07-01) -
Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab
by: Angela Fico, et al.
Published: (2025-05-01) -
Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis
by: Tiago Torres, et al.
Published: (2025-03-01) -
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
by: Lisa Schaeffer, et al.
Published: (2024-12-01) -
Analysis and mining of brodalumab adverse events based on FAERS database
by: Yue Wan, et al.
Published: (2025-05-01)